News for Healthier Living

AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies

Breast cancer is the most common cancer diagnosed in U.S. women. In hormone receptor positive, HER2 negative advanced cases, resistance to first line endocrine therapy is common. An estrogen receptor alpha gene mutation, ESR1m, drives resistance in nearly half of these patients, leaving them on ineffective treatment until radiologic progression is detected.

October 16, 2026


October 17 2026

October 16 2026

October 15 2026

October 14 2026

October 13 2026

October 12 2026

October 11 2026

October 10 2026

October 9 2026

October 8 2026

October 7 2026

October 6 2026

October 5 2026